system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adolescent, Adult, Aged, Antitubercular Agents, B-Lymphocytes, Cohort Studies, Complement C1q, Complement C2, Down-Regulation, Drug Therapy, Combination, Gene Expression Profiling, Gene Expression Regulation, Humans, Immunity, Humoral, Isoniazid, Male, Middle Aged, Mycobacterium tuberculosis, Oligonucleotide Array Sequence Analysis, Prospective Studies, Rifampin, Tuberculosis, Pulmonary, Up-Regulation, Young Adult.
user
Do distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response? Context: Accurate assessment of treatment efficacy would facilitate clinical trials of new antituberculosis drugs. We hypothesized that early alterations in peripheral immunity could be measured by gene expression profiling in tuberculosis patients undergoing successful conventional combination treatment. Ex vivo blood samples from 27 pulmonary tuberculosis patients were assayed at diagnosis and during treatment. RNA was processed and hybridized to Affymetrix GeneChips, to determine expression of over 47,000 transcripts. There were significant ≥ 2-fold changes in expression of >4000 genes during treatment. Rapid, large-scale changes were detected, with down-regulated expression of 1261 genes within the first week, including inflammatory markers such as complement components C1q and C2. This was followed by slower changes in expression of different networks of genes, including a later increase in expression of B-cell markers, transcription factors, and signaling molecules.
assistant
The fast initial down-regulation of expression of inflammatory mediators coincided with rapid killing of actively dividing bacilli, whereas slower delayed changes occurred as drugs acted on dormant bacilli and coincided with lung pathology resolution. Measurement of biosignatures during clinical trials of new drugs could be useful predictors of rapid bactericidal or sterilizing drug activity, and would expedite the licensing of new treatment regimens. Final Decision: yes